Pfizer’s Antiviral Drug May Have Potential as Long COVID Treatment 06/06/2022 Maayan Hoffman Scientists and doctors are beginning to eye Paxlovid, the antiviral medicine developed by Pfizer to protect vulnerable people from severe disease, as a potential treatment for lingering COVID-19 symptoms after single patients report that the medicine has helped to reduce their symptoms. Long COVID affects as many as one in five people infected by the […] Continue reading -> Scientists Might Never Determine Cause for Mysterious Acute Hepatitis Cases 31/05/2022 Maayan Hoffman Just days after the World Health Organization (WHO) announced that 650 total cases – and another 99 suspected cases – of mysterious acute hepatitis have been discovered in 33 countries worldwide, a top virologist has told Health Policy Watch that doctors and scientists may fail to ever find the root cause of the illness. “There […] Continue reading -> Massive Covid-19 Outbreak in Unvaccinated North Korea Raises Fresh Pandemic Concerns 17/05/2022 Aishwarya Tendolkar Nearly 1.4 million people in the Democratic People’s Republic of Korea (DPR Korea) are suspected of having been infected with COVID-19 in just the past three weeks, WHO officials said today. The global health agency has offered diagnostics, vaccines, medicines and other support, but with no clear response to date from the isolated Asian nation […] Continue reading -> COVID-19 Delta Variant Could Re-emerge – Concludes Study of SARS-CoV2 Virus Variants in Sewage 11/05/2022 Maayan Hoffman While the Omicron COVID-19 variant appears to be diminishing, it is possible that there could be a resurgence of the Delta variant in the coming months in some countries, according to a team of researchers from Ben-Gurion University (BGU) of the Negev studying the prevalence of SARS-CoV2 virus variants in sewage. The warning comes following […] Continue reading -> Three COVID-19 vaccine doses prove more protective than two in new study 10/05/2022 Maayan Hoffman A third shot of the Pfizer mRNA COVID-19 vaccine boosted vaccine effectiveness against infection, which had been diminished five to six months after the second vaccine dose, according to a study of over 12,000 healthcare workers released this week by Nature. The study was conducted in Israel by Sheba Medical Center and involved 12,413 health workers […] Continue reading -> Following USA – WHO Reports on Wave of Acute Childhood Hepatitis in the UK and Ireland 18/04/2022 Elaine Ruth Fletcher The World Health Organization has reported that it is investigating some 74 cases of acute childhood hepatitis, of an unknown origin, in the United Kingdom along with five suspected and confirmed cases in the Republic of Ireland. That follows on previous reports of similar, severe hepatitis cases of an unknown origin among a cluster of […] Continue reading -> Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Scientists Might Never Determine Cause for Mysterious Acute Hepatitis Cases 31/05/2022 Maayan Hoffman Just days after the World Health Organization (WHO) announced that 650 total cases – and another 99 suspected cases – of mysterious acute hepatitis have been discovered in 33 countries worldwide, a top virologist has told Health Policy Watch that doctors and scientists may fail to ever find the root cause of the illness. “There […] Continue reading -> Massive Covid-19 Outbreak in Unvaccinated North Korea Raises Fresh Pandemic Concerns 17/05/2022 Aishwarya Tendolkar Nearly 1.4 million people in the Democratic People’s Republic of Korea (DPR Korea) are suspected of having been infected with COVID-19 in just the past three weeks, WHO officials said today. The global health agency has offered diagnostics, vaccines, medicines and other support, but with no clear response to date from the isolated Asian nation […] Continue reading -> COVID-19 Delta Variant Could Re-emerge – Concludes Study of SARS-CoV2 Virus Variants in Sewage 11/05/2022 Maayan Hoffman While the Omicron COVID-19 variant appears to be diminishing, it is possible that there could be a resurgence of the Delta variant in the coming months in some countries, according to a team of researchers from Ben-Gurion University (BGU) of the Negev studying the prevalence of SARS-CoV2 virus variants in sewage. The warning comes following […] Continue reading -> Three COVID-19 vaccine doses prove more protective than two in new study 10/05/2022 Maayan Hoffman A third shot of the Pfizer mRNA COVID-19 vaccine boosted vaccine effectiveness against infection, which had been diminished five to six months after the second vaccine dose, according to a study of over 12,000 healthcare workers released this week by Nature. The study was conducted in Israel by Sheba Medical Center and involved 12,413 health workers […] Continue reading -> Following USA – WHO Reports on Wave of Acute Childhood Hepatitis in the UK and Ireland 18/04/2022 Elaine Ruth Fletcher The World Health Organization has reported that it is investigating some 74 cases of acute childhood hepatitis, of an unknown origin, in the United Kingdom along with five suspected and confirmed cases in the Republic of Ireland. That follows on previous reports of similar, severe hepatitis cases of an unknown origin among a cluster of […] Continue reading -> Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Massive Covid-19 Outbreak in Unvaccinated North Korea Raises Fresh Pandemic Concerns 17/05/2022 Aishwarya Tendolkar Nearly 1.4 million people in the Democratic People’s Republic of Korea (DPR Korea) are suspected of having been infected with COVID-19 in just the past three weeks, WHO officials said today. The global health agency has offered diagnostics, vaccines, medicines and other support, but with no clear response to date from the isolated Asian nation […] Continue reading -> COVID-19 Delta Variant Could Re-emerge – Concludes Study of SARS-CoV2 Virus Variants in Sewage 11/05/2022 Maayan Hoffman While the Omicron COVID-19 variant appears to be diminishing, it is possible that there could be a resurgence of the Delta variant in the coming months in some countries, according to a team of researchers from Ben-Gurion University (BGU) of the Negev studying the prevalence of SARS-CoV2 virus variants in sewage. The warning comes following […] Continue reading -> Three COVID-19 vaccine doses prove more protective than two in new study 10/05/2022 Maayan Hoffman A third shot of the Pfizer mRNA COVID-19 vaccine boosted vaccine effectiveness against infection, which had been diminished five to six months after the second vaccine dose, according to a study of over 12,000 healthcare workers released this week by Nature. The study was conducted in Israel by Sheba Medical Center and involved 12,413 health workers […] Continue reading -> Following USA – WHO Reports on Wave of Acute Childhood Hepatitis in the UK and Ireland 18/04/2022 Elaine Ruth Fletcher The World Health Organization has reported that it is investigating some 74 cases of acute childhood hepatitis, of an unknown origin, in the United Kingdom along with five suspected and confirmed cases in the Republic of Ireland. That follows on previous reports of similar, severe hepatitis cases of an unknown origin among a cluster of […] Continue reading -> Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVID-19 Delta Variant Could Re-emerge – Concludes Study of SARS-CoV2 Virus Variants in Sewage 11/05/2022 Maayan Hoffman While the Omicron COVID-19 variant appears to be diminishing, it is possible that there could be a resurgence of the Delta variant in the coming months in some countries, according to a team of researchers from Ben-Gurion University (BGU) of the Negev studying the prevalence of SARS-CoV2 virus variants in sewage. The warning comes following […] Continue reading -> Three COVID-19 vaccine doses prove more protective than two in new study 10/05/2022 Maayan Hoffman A third shot of the Pfizer mRNA COVID-19 vaccine boosted vaccine effectiveness against infection, which had been diminished five to six months after the second vaccine dose, according to a study of over 12,000 healthcare workers released this week by Nature. The study was conducted in Israel by Sheba Medical Center and involved 12,413 health workers […] Continue reading -> Following USA – WHO Reports on Wave of Acute Childhood Hepatitis in the UK and Ireland 18/04/2022 Elaine Ruth Fletcher The World Health Organization has reported that it is investigating some 74 cases of acute childhood hepatitis, of an unknown origin, in the United Kingdom along with five suspected and confirmed cases in the Republic of Ireland. That follows on previous reports of similar, severe hepatitis cases of an unknown origin among a cluster of […] Continue reading -> Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Three COVID-19 vaccine doses prove more protective than two in new study 10/05/2022 Maayan Hoffman A third shot of the Pfizer mRNA COVID-19 vaccine boosted vaccine effectiveness against infection, which had been diminished five to six months after the second vaccine dose, according to a study of over 12,000 healthcare workers released this week by Nature. The study was conducted in Israel by Sheba Medical Center and involved 12,413 health workers […] Continue reading -> Following USA – WHO Reports on Wave of Acute Childhood Hepatitis in the UK and Ireland 18/04/2022 Elaine Ruth Fletcher The World Health Organization has reported that it is investigating some 74 cases of acute childhood hepatitis, of an unknown origin, in the United Kingdom along with five suspected and confirmed cases in the Republic of Ireland. That follows on previous reports of similar, severe hepatitis cases of an unknown origin among a cluster of […] Continue reading -> Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Following USA – WHO Reports on Wave of Acute Childhood Hepatitis in the UK and Ireland 18/04/2022 Elaine Ruth Fletcher The World Health Organization has reported that it is investigating some 74 cases of acute childhood hepatitis, of an unknown origin, in the United Kingdom along with five suspected and confirmed cases in the Republic of Ireland. That follows on previous reports of similar, severe hepatitis cases of an unknown origin among a cluster of […] Continue reading -> Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Posts navigation Older postsNewer posts